Last reviewed · How we verify
Pivmecillinam/augmentin
Pivmecillinam/augmentin is a Beta-lactam antibiotic combination Small molecule drug developed by Radboud University Medical Center. It is currently FDA-approved for Bacterial urinary tract infections, Lower respiratory tract infections, Skin and soft tissue infections. Also known as: Selexid, Amoxicillin/clavulanic acid.
Pivmecillinam is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while augmentin (amoxicillin/clavulanic acid) combines a beta-lactam with a beta-lactamase inhibitor to overcome resistance.
Pivmecillinam is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while augmentin (amoxicillin/clavulanic acid) combines a beta-lactam with a beta-lactamase inhibitor to overcome resistance. Used for Bacterial urinary tract infections, Lower respiratory tract infections, Skin and soft tissue infections.
At a glance
| Generic name | Pivmecillinam/augmentin |
|---|---|
| Also known as | Selexid, Amoxicillin/clavulanic acid |
| Sponsor | Radboud University Medical Center |
| Drug class | Beta-lactam antibiotic combination |
| Target | Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Pivmecillinam works by disrupting peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis. The combination with augmentin (amoxicillin/clavulanic acid) provides broader spectrum coverage by protecting the beta-lactam from enzymatic degradation via clavulanic acid's beta-lactamase inhibition, allowing activity against beta-lactamase-producing organisms.
Approved indications
- Bacterial urinary tract infections
- Lower respiratory tract infections
- Skin and soft tissue infections
Common side effects
- Diarrhea
- Nausea
- Rash
- Allergic reactions
Key clinical trials
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis (PHASE4)
- Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs (PHASE3)
- Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pivmecillinam/augmentin CI brief — competitive landscape report
- Pivmecillinam/augmentin updates RSS · CI watch RSS
- Radboud University Medical Center portfolio CI
Frequently asked questions about Pivmecillinam/augmentin
What is Pivmecillinam/augmentin?
How does Pivmecillinam/augmentin work?
What is Pivmecillinam/augmentin used for?
Who makes Pivmecillinam/augmentin?
Is Pivmecillinam/augmentin also known as anything else?
What drug class is Pivmecillinam/augmentin in?
What development phase is Pivmecillinam/augmentin in?
What are the side effects of Pivmecillinam/augmentin?
What does Pivmecillinam/augmentin target?
Related
- Drug class: All Beta-lactam antibiotic combination drugs
- Target: All drugs targeting Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
- Manufacturer: Radboud University Medical Center — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Bacterial urinary tract infections
- Indication: Drugs for Lower respiratory tract infections
- Indication: Drugs for Skin and soft tissue infections
- Also known as: Selexid, Amoxicillin/clavulanic acid
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing